Published on 29/12/2025

Risk Sharing Agreements in Emerging Markets in 2023

Risk sharing agreements (RSAs) have become an increasingly important strategy for pharmaceutical companies operating in emerging markets. These agreements are critical for enhancing market access while balancing the financial risks associated with the introduction of new therapies in jurisdictions with varied healthcare infrastructure and economic variability. This comprehensive guide provides an in-depth overview of forming, implementing, and evaluating risk sharing agreements in compliance with regulatory requirements across the US, UK, and EU.

Understanding Risk Sharing Agreements

Risk sharing agreements are contractual arrangements between payers and pharmaceutical companies that outline the terms for reimbursement tied to the performance of a therapy. The overarching goal of RSAs is to create a mutually beneficial arrangement where the costs of drugs are mitigated when their clinical effectiveness does not meet predetermined expectations.

In emerging markets, the landscape for RSAs can be particularly complex due to various factors, such as diverse healthcare systems, reimbursement challenges, and differing patient demographics. Understanding the fundamentals of these agreements is essential for organizations looking to penetrate these markets.

Step 1: Assessing Market Conditions

The initial step in establishing a risk sharing agreement involves a thorough evaluation of market conditions. Different emerging markets present distinct challenges and opportunities, determined by economic status, healthcare infrastructure, payer landscape, and regulatory environment.

• Healthcare Infrastructure: Understand the quality and accessibility of healthcare services in the intended market. Assess the availability of resources, including trained healthcare professionals and facilities.
• Payer Landscape: Identify key payers in the market, such as government insurance programs, private insurers, and out-of-pocket payment systems.
• Regulatory Environment: Review the regulations pertaining to pharmaceutical reimbursement and pricing. Different countries have varied expectations and frameworks that dictate the operational aspects of RSAs.

By employing emerging market access and pricing consulting services, companies can gain insights into local market dynamics, possibly utilizing analyses drawn from previous RSA implementations. The differences in how the agreements work can be observed across various countries, such as Brazil, India, and South Africa.

Step 2: Stakeholder Engagement

After conducting market assessments, stakeholder engagement is crucial. Engaging with relevant stakeholders helps in tailoring the RSA to fit the local context. This collection of stakeholders typically includes:

• Healthcare Providers: Physicians and hospitals that play a central role in prescribing therapies.
• Payers: Insurance companies and government payers who will ultimately be responsible for approving reimbursement for the product.
• Patients: Engaging with patient advocacy groups can provide insight into patient needs and expectations.
• Regulatory Bodies: Engaging with entities like the FDA, EMA, or MHRA ensures compliance with local regulations while fostering a collaborative relationship.

The input received from each stakeholder group enables pharmaceutical organizations to craft an RSA that reflects the values and practices of the local healthcare ecosystem. Building these relationships can also facilitate smoother approvals in subsequent steps.

Step 3: Designing the Risk Sharing Agreement

With stakeholder insights in hand, the next step involves designing the actual agreement. An RSA must incorporate specific elements that clearly define the terms of engagement, such as:

• Product Description: Clearly identify the therapeutic product, including indications and target populations.
• Performance Metrics: Establish measurable outcomes that will dictate the return on investment for both parties. These could include clinical outcomes, hospitalization rates, or adherence rates.
• Financial Terms: Clearly outline the risk-sharing aspects, including thresholds for reimbursement, pricing adjustments, or rebates.
• Duration of Agreement: Specify the length of the agreement and conditions for renewal or termination based on performance metrics.
• Data Sharing Agreements: Determine the extent of data-sharing between parties for tracking performance outcome metrics.

These components are vital in ensuring the agreement provides a clear framework that minimizes ambiguity and sets proper expectations for all partners involved. Regulatory compliance surrounding these agreements must also be a top priority to ensure they align with global regulations, including ICH standards.

Step 4: Approval Process and Documentation

After the design of the RSA, the approval process becomes the next challenge. Different regions and payers may require different documentation types or formats. Careful planning is essential to navigate this process effectively.

• Documentation Requirements: Prepare necessary forms, agreements, and evidence to support the RSA submission to local regulatory bodies and payers.
• Consult Regulatory Authorities: Engage with local regulatory entities to ensure that the proposed RSA complies with regional requirements. This can also facilitate quicker reviews and approvals.
• Negotiation Phase: Be prepared for negotiations with payers and stakeholders to adjust terms based on their feedback while maintaining the financial viability of the agreement for the product owner.

Document everything meticulously, as regulatory entities may require transparency throughout the process. Agreement drafts, stakeholder communications, and negotiation notes create a robust submission package that can withstand regulatory scrutiny.

Step 5: Implementation Strategies

Once the RSA has been approved, the implementation phase begins. It is crucial to follow methodical strategies to ensure that the agreement is effectively executed:

• Training Healthcare Providers: Educate healthcare providers about the RSA terms, the expected outcomes, and the importance of reporting relevant data for performance evaluation.
• Monitoring and Support: Establish a robust system for monitoring the performance of the therapy and assessing whether it meets the outlined metrics. Having a dedicated support team can help resolve issues that may arise during this phase.
• Regular Reviews: Create periodic performance review sessions with stakeholders to discuss data collected and potential adjustments needed based on interim results.

This ongoing interaction with stakeholders enhances trust and can lead to effective decision-making for any necessary adjustments required for the RSA’s success.

Step 6: Evaluation and Adjustments

Evaluation of the RSA’s outcomes is the final phase, and it is particularly essential to understand the therapeutic effectiveness versus the financial remuneration. The evaluation process typically includes:

• Outcome Measurement: Compare the indicated performance metrics with the actual outcomes observed during the implementation phase. The comparison will elucidate the efficacy of the agreement.
• Reporting Findings: Regularly report findings to all stakeholders, emphasizing areas of success and opportunities for improvement. This helps to maintain transparency and accountability.
• Negotiating Adjustments: Based on findings, it may become necessary to amend terms within the RSA to better align with observed performance. Trust between parties can significantly facilitate these negotiations.

Incorporating rigorous evaluation practices allows for real-time assessment and faster reaction to underperformance, ensuring that costs are restrained while patient access to effective treatments is maximized.

Conclusion: Risks and Best Practices

In conclusion, while risk sharing agreements present a viable tool for pharmaceutical companies to enhance market access in emerging markets, a clear understanding of local market dynamics, diligent stakeholder engagement, and thorough documentation processes are critical. By following the outlined steps and embracing best practices, pharmaceutical companies can effectively navigate the complexities of RSAs, delivering better healthcare outcomes while optimizing financial viability.

Organizations can leverage the insights gained from engaging in ClinicalTrials.gov and collaborating with experienced professionals familiar with global regulatory strategy to improve the chances of a successful RSA implementation in emerging markets.

As the landscape of pharmaceutical development continues to evolve, adopting a proactive approach to RSAs can yield significant benefits in optimizing pricing strategies while ensuring compliance with regulations like those from the FDA, EMA, and MHRA.